Antoni Martínez-Rubio

Antoni Martínez-Rubio

FACC FESC MD PhD

University Hospital of Sabadell, Sabadell, Spain

Biography

Dr Antoni Martinez Rubio , Jefe de Servicio de Cardiología del Hospital Parc Taulí de Sabadell (Barcelona, España).

Dr Martínez-Rubio is on the Editorial Board of European Cardiology Review.

Articles by Antoni Martínez-Rubio

Coronavirus Disease 2019 and Cardiac Arrhythmias

Antoni Martínez-Rubio, Soledad Ascoeta, Fadwa Taibi, et al

Published:

Citation: European Cardiology Review 2020;15:e66.

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

M Rizzo, I Colomer-Asenjo, M Sutil-Vega, et al

Citation: European Cardiology Review 2020;15:e31.

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

M Rizzo, I Colomer-Asenjo, G Cabello-Molina, et al

Citation: European Cardiology Review 2020;15:e32.

Differences in Clinical Characteristics, Results and Management of Patients Referred for Pharmacologic Cardiac Stress SPECT Depending on the Protocol Used

Pablo Del Castillo-Vásquez, Núria Casanovas, Marcel Santaló-Corcoy, et al

Citation: European Cardiology Review 2017;12(2):102.

Secondary Prevention in Patients with Non Valvular Atrial Fibrillation and Previous Stroke. Is It Possible to Have an Appropriate INR Control?

Mario DiazNuila-Alcazar, Daniel Valcárcel-Paz, Marcel Santaló-Corcoy, et al

Citation: European Cardiology Review 2017;12(2):103.

Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal

Antoni Martínez-Rubio, Mario DiazNuila-Alcazar, Anna Soria Cadena, et al

Published:

Citation: European Cardiology Review 2016;11(2):118–22

Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?

Antoni Martínez-Rubio, Gheorghe-Andrei Dan,

Citation: European Cardiology Review 2016;11(2):115–7

Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors

Antoni Martínez-Rubio, Román Freixa Pamias,

Citation: European Cardiology Review 2017;12(1):30–2